Silence Therapeutics PLC Sponsored ADR SLN 深 沪
已收盘 07-02 16:00:00 美东时间
10.39
-0.110
-1.05%
华盛通- 最 高11.055
- 今 开10.66
- 成交量 69.67万股
- 最 低 10.17
- 昨 收 10.50
- 总市值 4.91亿
- 52周最高 11.0599
- 市盈率 静 --
- 换手率 1.48%
- 52周最低 4.19
- 委 比 -83.99%
- 总股本 4723.46万
- 历史最高 35.00
- 量 比 0.72
- 振 幅 8.43%
- 历史最低 1.97
- 每 手 1
- 风险率 1.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | NVCT飙升近40%！与海思科达成许可协议，获两款创新药海外独家开发权；WEN大涨超25%
NVCT飙升近40%！与海思科达成许可协议，获两款创新药海外独家开发权；WEN大涨超25%，散户“集火”下或迎逼空行情；DFTX涨超16%>>
06-25 15:45
This $300 Million Biotech May Be Deeply Mispriced: Analyst
Cantor Fitzgerald initiated coverage of Silence Therapeutics Plc (NASDAQ:SLN) with an Overweight rating, arguing that the biotech’s lead candidate divesiran could emerge as a major challenger in the polycythemia vera market, with upcoming Phase 2 data expected in August serving as a potentially tran...
06-25 02:22
Silence Therapeutics股价因Cantor Fitzgerald上调评级上涨
核心事件：Cantor Fitzgerald启动对Silence Therapeutics PLC（NASDAQ:SLN）的覆盖，给予其“增持”评级，推动该股周...
06-24 23:48
Cantor Fitzgerald Initiates Coverage On Silence Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Silence Therapeutics (NASDAQ:SLN) with a Overweight rating.
06-24 22:01
美股大行评级 | 花旗维持美光科技"买入"评级！目标价从840美元升至1200美元
今日重点评级关注：Chardan Capital：维持SAB Biotherapeutics"买入"评级，目标价从14美元升至16美元；Northland Capital Markets：维持Applied Digital"跑赢大市"评级，目标价从56美元升至82美元
06-18 19:08
Silence Therapeutics Presents Follow-Up, Quality-Of-Life Data From Phase 1 SANRECO Study Evaluating Divesiran In 21 Phlebotomy-Dependent Patients With Polycythemia Vera At EHA 2026 Annual Congress.
New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life Follow-up data show substantial reductions in phlebotomy use persisting after final dose Phase 2 SANRECO study evaluating Q6W and Q12W dosing remains on-track for topline results in Augu...
06-12 01:20
Silence Therapeutics shares are trading lower after the company reported worse-than-expected Q1 sales results.
Silence Therapeutics shares are trading lower after the company reported worse-...
05-08 00:48
Silence Therapeutics Q1 EPS $(0.11) Beats $(0.21) Estimate, Sales $422.000K Miss $2.439M Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 45 percent increase over losses of $(0.20) per share from
05-07 20:20
Why Urgent.ly Shares Are Trading Higher By Around 159%; Here Are 20 Stocks Moving Premarket
Urgent.ly shares surged in pre-market trading after agreement to be acquired by Agero for $5.50 per share. Also reported better-than-expected Q4 results.
03-16 17:39
Silence Therapeutics shares are trading lower after the company reported worse-than-expected Q4 sales results.
Silence Therapeutics shares are trading lower after the company reported worse-...
03-06 00:12
